Response to Comment—Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published in Lancet Oncology
We read the commentary by Fusco et al [...]
Main Authors: | Noopur Raje, Evangelos Terpos, Danielle D. Jandial |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-05-01
|
Series: | Dentistry Journal |
Subjects: | |
Online Access: | https://www.mdpi.com/2304-6767/7/2/54 |
Similar Items
-
Intraosseous Squamous Cell Carcinoma Associated with Denosumab-Induced Osteonecrosis of the Jaw
by: Sandra Bacián Martínez, et al.
Published: (2021-08-01) -
Medication-Related Osteonecrosis of the Jaws Initiated by Zoledronic Acid and Potential Pathophysiology
by: Aya Alsalih, et al.
Published: (2021-07-01) -
A Model for Osteonecrosis of the Jaw with Zoledronate Treatment following Repeated Major Trauma.
by: R Nicole Howie, et al.
Published: (2015-01-01) -
Long-term use of denosumab and its association with skeletal-related events and osteonecrosis of the jaw
by: Pei-An Fu, et al.
Published: (2023-05-01) -
Evaluation of Jaw Osteonecrosis Following Intra-Ligament Anesthesia in Zoledronate-Treated Rats: a Histological Evaluation
by: Saeed Moradi, et al.
Published: (2023-03-01)